Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834027 | 1.00 | SMYD3 (0.32) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4845714 | 0.84 | SMYD3 (0.31) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4833164 | 0.84 | SMYD3 (0.31) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4833017 | 0.84 | SMYD3 (0.31) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4842728 | 0.84 | NR1I2 (0.33) | — | |
| SCHEMBL4842345 | 0.84 | NR1I2 (0.33) | — | |
| SCHEMBL4838270 | 0.84 | NR1I2 (0.33) | — | |
| SCHEMBL4844996 | 0.84 | NR1I2 (0.33) | — | |
| SCHEMBL4839652 | 0.84 | PSEN1 (0.35) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4837998 | 0.84 | PSEN1 (0.35) | SMYD3PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | claimed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | claimed |
| EP-1636196-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004080983-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183732-A1 | Novel lactams and uses thereof | BACE1, BACE2, APP | SMYD3 4425/4885PSEN1 6/4885PSEN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.